SNGX•Soligenix reported no revenue and a third-quarter net loss of $1.1 million, or $0.05 per share, narrowed year over year as research and development costs fell. The company expects its cash to fund operations into the second quarter of 2028.
Soligenix reported no revenue for the third quarter of 2026 and a net loss of $1.1 million, or $0.05 per share. The loss narrowed year over year, mainly due to lower research and development expenses after the company ended its FLASH2 trial and HyBryte development, as well as a gain from extinguishing vendor liabilities.
The company expects cash to fund operations into the second quarter of 2028. It is evaluating partnership, licensing, merger and acquisition, and government funding opportunities, and said maintaining its Nasdaq listing is a priority for strategic flexibility.
